$Terns Pharmaceuticals, Inc.(TERN)$
$Cardiff Oncology, Inc.(CRDF)$
Tired of boring 8% returns? These tiny biotech stocks are straight-up lottery tickets — small bets that exploded 6x–8x (or got BOUGHT OUT) because of one magic formula:
Insane clinical data + massive cash war chests + “clean” assets = Big Pharma takeover bait.
Why now? Big Pharma faces a $400 BILLION revenue cliff by 2030. They’re starving for new drugs and paying premiums to snatch these gems.
Here’s the playbook that already minted winners:
1. Erasca (ERAS) – The “Perfect Storm” Lottery Ticket
Result: ~$2 → $16.40 = 800%+ rocket ship in months!
Core weapon: ERAS-0015, a “molecular glue” attacking the undruggable RAS mutations behind pancreatic, lung & killer cancers.
January 2026 data drop: Responses at tiny 8 mg doses. Jaw-dropping efficacy + almost zero serious side effects.
Then they raised $259 MILLION at sky-high prices (no brutal dilution) and locked in full global rights + patents to 2043.
Big Pharma is drooling. Clean asset + fat cash + monster data = instant acquisition bait.
2. Terns Pharmaceuticals (TERN) – The “Lightning Strike” Winner
Result: ~$7 → $53 = 666% explosion… then BOUGHT OUT by Merck for $6.7 BILLION on March 25, 2026!
They went ALL-IN on TERN-701 (best-in-class CML drug) after ditching a risky obesity program.
ASH 2025 data: 64–75% response rates in tough patients with almost no severe side effects.
Raised $740+ MILLION, stacked ~$1 BILLION cash, runway to 2031.
Merck just validated the entire thesis in real time. Game over — winners cashed out huge.
Same repeatable pattern: Killer data + no-dilution cash + laser-focused assets = Big Pharma check in the mail.
3. Cullinan Therapeutics (CGEM) – Your Next 10x Lottery Ticket?
“Dual-engine” play: oncology + autoimmune diseases (huge patient pools).
Smart moves: Killed weak programs, now all-in on CLN-978 (CD19xCD3 T-cell engager expanding into lupus & rheumatoid arthritis) + zipalertinib (already in NDA for lung cancer).
Cash fortress: $439 MILLION — runway into 2029. Zero near-term dilution panic.
2026 catalysts raining: Q2 autoimmune data, more dose-escalation reads, pivotal results coming.
Wall Street (Citi) screaming $30–$33 targets while it sits around $13.
This one just needs the “ignition” data to copy ERAS/TERN and fly.
4. Cardiff Oncology (CRDF) – The “Concentrated All-In Bet”
100% focused on one potential blockbuster: Onvansertib (oral PLK1 inhibitor) for first-line RAS-mutated metastatic colorectal cancer — a disease stuck in the mud for 20+ years.
January 2026 Phase 2 bombshell: 72% response rate (vs 43% control) + massive 63% drop in progression risk at 30 mg dose. Clean safety.
Pfizer already owns a chunk (bought at higher prices). FDA meeting coming H1 2026 to green-light Phase 3.
Only weakness: $58M cash (dilution risk). Fix that and this could be the next 10-bagger.
Bottom line: In this patent-cliff frenzy, the formula is working right now. Two tickets already paid out massive. CGEM and CRDF have the exact same setup — just waiting for their winning numbers.
⚠️ COLD HARD TRUTH (LOTTERY TICKET WARNING)
These are NOT safe blue-chip stocks.
One bad data read = stock can CRASH 70-90% overnight.
Cash runs out = brutal dilution.
Timelines stretch = boredom kills gains.
Binary events only.
Position size tiny — money you can literally light on fire and not cry. This is gambling money for explosive upside, not your retirement account.
@TigerPM @TigerStars @TigerObserver @Daily_Discussion @Tiger_comments
Comments